HLUYY - Lundbeck Entering A Period Of Heightened Uncertainty
The next few years are going to seriously challenge the skills of H. Lundbeck’s (OTCPK:HLUYY) (LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan Luthman, as the company has to contend with serious erosion in its mature portfolio, a very weak late-stage pipeline (not to mention risky early-stage assets), and the challenges that go with M&A and in-licensing. While Lundbeck does head into this difficult period with some strong drugs still early in their commercialization and a very clean balance sheet, investors need only look at Roche (OTCQX:RHHBY) to